CN1313465C - 杂多环化合物及其用于制备代谢性谷氨酸受体拮抗剂的应用 - Google Patents

杂多环化合物及其用于制备代谢性谷氨酸受体拮抗剂的应用 Download PDF

Info

Publication number
CN1313465C
CN1313465C CNB008145024A CN00814502A CN1313465C CN 1313465 C CN1313465 C CN 1313465C CN B008145024 A CNB008145024 A CN B008145024A CN 00814502 A CN00814502 A CN 00814502A CN 1313465 C CN1313465 C CN 1313465C
Authority
CN
China
Prior art keywords
oxadiazole
pyridyl
oxazole
cyanophenyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008145024A
Other languages
English (en)
Chinese (zh)
Other versions
CN1379775A (zh
Inventor
B·C·范瓦格宁
T·M·斯托尔曼
S·T·莫埃
S·M·舍汉
D·A·麦莱奥德
D·L·史密斯
M·B·伊萨尔克
A·斯拉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
NPS Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22530400&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1313465(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by NPS Pharmaceuticals Inc filed Critical NPS Pharmaceuticals Inc
Publication of CN1379775A publication Critical patent/CN1379775A/zh
Application granted granted Critical
Publication of CN1313465C publication Critical patent/CN1313465C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CNB008145024A 1999-08-19 2000-08-18 杂多环化合物及其用于制备代谢性谷氨酸受体拮抗剂的应用 Expired - Fee Related CN1313465C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14946499P 1999-08-19 1999-08-19
US60/149,464 1999-08-19

Publications (2)

Publication Number Publication Date
CN1379775A CN1379775A (zh) 2002-11-13
CN1313465C true CN1313465C (zh) 2007-05-02

Family

ID=22530400

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008145024A Expired - Fee Related CN1313465C (zh) 1999-08-19 2000-08-18 杂多环化合物及其用于制备代谢性谷氨酸受体拮抗剂的应用

Country Status (27)

Country Link
EP (1) EP1210344B1 (https=)
JP (2) JP3790472B2 (https=)
KR (1) KR100875222B1 (https=)
CN (1) CN1313465C (https=)
AT (1) ATE307129T1 (https=)
AU (1) AU780191B2 (https=)
BG (1) BG65586B1 (https=)
BR (1) BR0013427A (https=)
CA (1) CA2381975A1 (https=)
CY (1) CY1105253T1 (https=)
CZ (1) CZ2002599A3 (https=)
DE (1) DE60023318T2 (https=)
DK (1) DK1210344T3 (https=)
EE (1) EE200200079A (https=)
ES (1) ES2250177T3 (https=)
HU (1) HUP0202757A3 (https=)
IL (2) IL148157A0 (https=)
IS (1) IS6275A (https=)
MX (1) MXPA02001764A (https=)
NO (1) NO322460B1 (https=)
NZ (1) NZ517221A (https=)
PL (1) PL353825A1 (https=)
RU (1) RU2296127C9 (https=)
SK (1) SK2512002A3 (https=)
UA (1) UA75871C2 (https=)
WO (1) WO2001012627A1 (https=)
ZA (1) ZA200201358B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105143214A (zh) * 2013-02-15 2015-12-09 孟山都技术公司 用于控制线虫害虫的3,5-二取代的-4,5-二氢-1,2,4-噁二唑

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
CN1853630A (zh) * 2001-02-21 2006-11-01 Nps制药公司 杂多环化合物及其在亲代谢的谷氨酸受体拮抗剂中的应用
US6916821B2 (en) 2001-04-02 2005-07-12 Brown University Methods of treating disorders with Group I mGluR antagonists
AU2002307049A1 (en) 2001-04-02 2002-10-15 Brown University Research Foundation Use of mglur5 antagonists in the manufacture of a medicament in the treatment of autism, mental retardation, schizophrenia
CA2469821C (en) * 2001-12-18 2009-10-20 Merck & Co., Inc. Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
WO2003051833A2 (en) * 2001-12-18 2003-06-26 Merck & Co., Inc. Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
CA2470612A1 (en) * 2001-12-19 2003-07-03 Merck & Co., Inc. Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
DE60334781D1 (de) * 2002-03-12 2010-12-16 Merck Sharp & Dohme Di-aryl-substituierte tetrazol-modulatoren des metabotropen glutamat-rezeptors-5
US7964609B2 (en) 2002-06-20 2011-06-21 Astrazeneca Ab Use of mGluR5 antagonists for the treatment of gerd
SE0201943D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New use
AU2003264018A1 (en) 2002-08-09 2004-02-25 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
IL166510A0 (en) 2002-08-09 2006-01-15 Nps Pharma Inc 1,2,4"oxadiazole as modulators of metabotropic glutamate receptor-5
MXPA05001592A (es) * 2002-08-09 2005-05-05 Astrazeneca Ab Oxadiazoles como moduladores de receptor-5 de glutamato metabotropico.
GB0303503D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
CA2521396A1 (en) * 2003-04-04 2004-10-21 Merck & Co., Inc. Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5
US20060252741A1 (en) * 2003-05-15 2006-11-09 Colandrea Vincent J 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
WO2005060961A2 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
JP4958560B2 (ja) * 2003-12-24 2012-06-20 プロシディオン・リミテッド Ｇｐｃｒ受容体作動薬としてのヘテロ環誘導体
US7585881B2 (en) 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
RU2381226C2 (ru) * 2004-02-18 2010-02-10 Астразенека Аб Полигетероциклические соединения и их применение в качестве антагонистов метаботропного рецептора глутамата
DK1716152T3 (da) * 2004-02-18 2008-11-03 Astrazeneca Ab Kondenserade heterocykliske forbindelser og deres anvendelse som metabotrope receptorantagonister til behandling af gastrointentinde lidelser
TW200538108A (en) 2004-02-19 2005-12-01 Astrazeneca Ab Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
US7858800B2 (en) * 2004-06-30 2010-12-28 Banyu Pharmaceutical Co., Ltd. Biaryl derivatives
KR100621192B1 (ko) * 2004-10-13 2006-09-19 한국화학연구원 무스카린 수용체 작용물질로서 작용하는1,2,3,4-테트라하이드로피리미디닐-1,2,4-옥사다이아졸유도체와 이의 제조방법
JP4557685B2 (ja) 2004-11-15 2010-10-06 独立行政法人理化学研究所 蛍光蛋白質
AU2006205920B2 (en) 2005-01-14 2012-11-15 F. Hoffmann-La Roche Ag Thiazole-4-carboxamide derivatives as mGluR5 antagonists
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
EP1896011A1 (en) * 2005-06-28 2008-03-12 AstraZeneca AB New use
AR058439A1 (es) 2005-07-26 2008-02-06 Portela & Ca Sa Derivados de nitrocatecol como inhibidores de comt. procesos de obtencion y composiciones farmaceuticas.
AR058807A1 (es) 2005-09-29 2008-02-27 Astrazeneca Ab 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5
ATE553108T1 (de) 2005-11-08 2012-04-15 Hoffmann La Roche Thiazoloä4,5-cüpyridinderivative als antagonisten des mglu5-rezeptors
US7951824B2 (en) 2006-02-17 2011-05-31 Hoffman-La Roche Inc. 4-aryl-pyridine-2-carboxyamide derivatives
MX2008012738A (es) * 2006-04-03 2009-02-06 Astellas Pharma Inc Heterocompuesto.
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
US20100234349A1 (en) * 2006-09-04 2010-09-16 Olsen Gunnar M Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
TWI392671B (zh) 2006-09-07 2013-04-11 Actelion Pharmaceuticals Ltd 吡啶-４-基衍生物
ES2400163T3 (es) 2006-09-08 2013-04-08 Actelion Pharmaceuticals Ltd. Derivados de piridil-3-ilo como agentes de inmunomodulación
MX2009002915A (es) 2006-09-21 2009-03-31 Actelion Pharmaceuticals Ltd Derivados de fenilo y su uso como inmunomoduladores.
EP2481410B1 (en) 2007-01-31 2016-07-13 BIAL - Portela & Ca., S.A. Nitrocatechol derivates as COMT inhibitors administered with a specific dosage regime
PT2125797E (pt) 2007-03-16 2014-03-11 Actelion Pharmaceuticals Ltd Derivados aminopiridina como agonistas do receptor s1p1/edg1
US8598208B2 (en) 2007-08-17 2013-12-03 Actelion Pharmaceuticals Ltd. Pyridine derivatives as S1P1/EDG1 receptor modulators
CA2703909A1 (en) 2007-10-31 2009-05-07 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
RU2010121969A (ru) 2007-11-01 2011-12-10 Актелион Фармасьютиклз Лтд (Ch) Новые производные пиримидина
US8288402B2 (en) * 2007-12-20 2012-10-16 Bayer Intellectual Property Gmbh 4-(4-cyano-2-thioaryl)dihydropyrimidinones and their use
EP2732819B1 (en) 2008-02-07 2019-10-16 Massachusetts Eye & Ear Infirmary Compounds that enhance Atoh-1 expression
AU2009220893A1 (en) 2008-03-07 2009-09-11 Actelion Pharmaceuticals Ltd Novel aminomethyl benzene derivatives
KR20110002462A (ko) 2008-03-17 2011-01-07 바이알 - 포르텔라 앤드 씨에이 에스에이 5-[3-(2,5-디클로로-4,6-디메틸-1-옥시-피리딘-3-일)-[1,2,4]옥사디아졸-5-일]-3-나이트로벤젠-1,2-디올의 결정형
ES2534199T3 (es) 2008-10-31 2015-04-20 Merck Sharp & Dohme Corp. Antagonistas del receptor P2X3 para el tratamiento del dolor
DE102008057364A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041242A1 (de) 2009-09-11 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057344A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057343A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041241A1 (de) 2009-09-11 2011-08-04 Bayer Schering Pharma Aktiengesellschaft, 13353 Substituierte Aryl-Verbindungen und ihre Verwendung
US8946231B2 (en) 2009-03-23 2015-02-03 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
WO2010111058A1 (en) 2009-03-23 2010-09-30 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
AU2010229144B2 (en) 2009-03-23 2012-07-12 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
AU2010231961B2 (en) 2009-04-01 2015-05-21 Bial - Portela & Ca., S.A. Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof
CA2758587A1 (en) * 2009-04-13 2010-10-21 Irm Llc Compositions and methods for modulating retinol binding to retinol binding protein 4 (rbp4)
CN102471328B (zh) 2009-07-16 2015-04-01 埃科特莱茵药品有限公司 吡啶-4-基衍生物
US20130058915A1 (en) 2010-03-02 2013-03-07 Children's Medica Center Corporation Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
HRP20150919T1 (hr) 2011-01-19 2015-09-25 Actelion Pharmaceuticals Ltd. Derivati 2-metoksi-piridin-4-ila
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
WO2013089573A1 (en) 2011-12-13 2013-06-20 BIAL - PORTELA & Cª., S.A. Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor
JP5946288B2 (ja) * 2012-02-24 2016-07-06 公立大学法人名古屋市立大学 新規ヒドロキサム酸誘導体及びその用途
EP2853532B1 (en) * 2013-09-28 2020-12-09 Instytut Farmakologii Polskiej Akademii Nauk 1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III
JP2018500300A (ja) 2014-11-28 2018-01-11 ノヴィファーマ，エス．アー． パーキンソン病を遅延させるための医薬
BR112017024785B1 (pt) 2015-05-20 2022-05-17 Idorsia Pharmaceuticals Ltd Forma cristalina do composto (s)-3-{4-[5-(2-ciclopentil-6-metoxi-piridin-4-il)-[1,2,4] oxadiazol-3- il]-2-etil-6-metilfenoxi}-propano-1,2-diol, composição farmacêutica, e, uso
AU2016281346B2 (en) 2015-06-23 2020-01-02 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, or pharmaceutically acceptable salt thereof
CN108883104A (zh) * 2016-03-30 2018-11-23 森泰克希斯公司 用于在治疗成熟脑损伤中使用的mGluR5的负性变构调节剂
DK3904350T3 (da) * 2018-04-12 2023-11-13 Bayer Ag N-(cyclopropylmethyl)-5-(methylsulfonyl)-n-{1-[1-(pyrimidin-2-yl)-1h-1,2,4-triazol-5-yl]ethyl}benzamidderivater og de tilsvarende pyridincarboxamidderivater som pesticider
KR102276327B1 (ko) * 2019-06-25 2021-07-12 연세대학교 산학협력단 신규 옥사다이아졸 화합물 및 이를 포함하는 당뇨 예방 또는 치료용 조성물
AU2020341464A1 (en) * 2019-09-05 2022-04-21 Trevena, Inc. Methods of treating epilepsy using the same

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1149011B (de) * 1960-04-05 1963-05-22 Hoechst Ag Verfahren zur Herstellung von 3, 5-disubstituierten 1, 2, 4-Oxdiazolen
US3647809A (en) * 1968-04-26 1972-03-07 Chinoin Gyogyszer Es Vegyeszet Certain pyridyl-1 2 4-oxadiazole derivatives
US4003909A (en) * 1974-07-22 1977-01-18 E. R. Squibb & Sons, Inc. [(1,2,4-Oxadiazol-3-yl)phenyl]carbamic or thiocarbamic acid esters
US4022901A (en) * 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
WO1994022846A1 (en) * 1993-03-30 1994-10-13 Pfizer Inc. Compounds enhancing antitumor activity of other cytotoxic agents
US5554630A (en) * 1993-03-24 1996-09-10 Neurosearch A/S Benzimidazole compounds
WO1997003967A1 (en) * 1995-07-22 1997-02-06 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
WO1998017652A1 (de) * 1996-10-18 1998-04-30 Boehringer Ingelheim Pharma Kg Oxadiazole, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU675484B2 (en) * 1993-03-24 1997-02-06 Neurosearch A/S Benzimidazole compounds, their use and preparation
RU2135493C1 (ru) * 1995-04-21 1999-08-27 Нюросерч А/С Производное бензимидазола, фармацевтический состав и способ модуляции гамка-рецепторного комплекса
JP2001524468A (ja) * 1997-11-21 2001-12-04 エヌピーエス ファーマシューティカルズ インコーポレーテッド 中枢神経系疾患を治療するための代謝調節型グルタミン酸受容体アンタゴニスト

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1149011B (de) * 1960-04-05 1963-05-22 Hoechst Ag Verfahren zur Herstellung von 3, 5-disubstituierten 1, 2, 4-Oxdiazolen
US3647809A (en) * 1968-04-26 1972-03-07 Chinoin Gyogyszer Es Vegyeszet Certain pyridyl-1 2 4-oxadiazole derivatives
US4003909A (en) * 1974-07-22 1977-01-18 E. R. Squibb & Sons, Inc. [(1,2,4-Oxadiazol-3-yl)phenyl]carbamic or thiocarbamic acid esters
US4022901A (en) * 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
US5554630A (en) * 1993-03-24 1996-09-10 Neurosearch A/S Benzimidazole compounds
WO1994022846A1 (en) * 1993-03-30 1994-10-13 Pfizer Inc. Compounds enhancing antitumor activity of other cytotoxic agents
WO1997003967A1 (en) * 1995-07-22 1997-02-06 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
WO1998017652A1 (de) * 1996-10-18 1998-04-30 Boehringer Ingelheim Pharma Kg Oxadiazole, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
CN1086698C (zh) * 1996-10-18 2002-06-26 贝林格尔英格海姆法玛公司 噁二唑,其制备方法及其作为药物组合物的用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCHLEPPNIK NITRLE OXIDE CYCLOADDITION ROUTES TO2-(ISOXAZOLYL)-BENZOATES AND2-(1,2,4-OXADIAZOL-3-YL)BENZOATES R K HOWE F M,J.of Het.Chem 1982 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105143214A (zh) * 2013-02-15 2015-12-09 孟山都技术公司 用于控制线虫害虫的3,5-二取代的-4,5-二氢-1,2,4-噁二唑
CN105143214B (zh) * 2013-02-15 2018-04-03 孟山都技术公司 用于控制线虫害虫的3,5‑二取代的‑4,5‑二氢‑1,2,4‑噁二唑
CN108371182A (zh) * 2013-02-15 2018-08-07 孟山都技术公司 用于控制线虫害虫的3,5-二取代的-4,5-二氢-1,2,4-噁二唑

Also Published As

Publication number Publication date
SK2512002A3 (en) 2002-07-02
CY1105253T1 (el) 2010-03-03
EE200200079A (et) 2003-06-16
ATE307129T1 (de) 2005-11-15
PL353825A1 (en) 2003-12-01
HUP0202757A3 (en) 2006-03-28
DE60023318D1 (de) 2006-03-02
UA75871C2 (en) 2006-06-15
KR20020038731A (ko) 2002-05-23
NO20020823D0 (no) 2002-02-19
DK1210344T3 (da) 2006-03-06
CN1379775A (zh) 2002-11-13
NZ517221A (en) 2004-01-30
JP2006143746A (ja) 2006-06-08
BR0013427A (pt) 2002-07-30
JP3790472B2 (ja) 2006-06-28
CA2381975A1 (en) 2001-02-22
RU2296127C2 (ru) 2007-03-27
JP2003507378A (ja) 2003-02-25
AU780191B2 (en) 2005-03-03
ES2250177T3 (es) 2006-04-16
MXPA02001764A (es) 2004-03-19
AU6782400A (en) 2001-03-13
WO2001012627A1 (en) 2001-02-22
NO20020823L (no) 2002-04-17
EP1210344B1 (en) 2005-10-19
BG65586B1 (bg) 2009-01-30
CZ2002599A3 (cs) 2002-06-12
IL148157A0 (en) 2002-09-12
DE60023318T2 (de) 2006-07-20
RU2296127C9 (ru) 2007-08-27
ZA200201358B (en) 2003-07-30
NO322460B1 (no) 2006-10-09
HUP0202757A2 (hu) 2002-12-28
HK1047929A1 (en) 2003-03-14
BG106493A (en) 2003-01-31
EP1210344A1 (en) 2002-06-05
IL148157A (en) 2007-07-04
IS6275A (is) 2002-02-18
KR100875222B1 (ko) 2008-12-19

Similar Documents

Publication Publication Date Title
CN1313465C (zh) 杂多环化合物及其用于制备代谢性谷氨酸受体拮抗剂的应用
CN1158264C (zh) 用于治疗中枢神经系统疾病的代谢性谷氨酸受体拮抗剂
CN1227236C (zh) 取代的咪唑神经肽yy5受体拮抗剂
CN1211384C (zh) 噻二唑基和噁二唑基苯基噁唑烷酮抗菌剂
CN1103770C (zh) 喹喔啉二酮化合物
CN1853630A (zh) 杂多环化合物及其在亲代谢的谷氨酸受体拮抗剂中的应用
CN1102648A (zh) 取代的单-和双-吡啶基甲基吡啶酮类化合物
CN1057837A (zh) 取代的2-苯并[c]呋喃酮和杂环2-苯并[c]呋喃酮
CN1234025A (zh) 1－苯基－苯并咪唑类化合物及其作为baga－a受体调节剂的用途
CN1204327A (zh) 药用活性喹唑啉类化合物
CN1805945A (zh) 作为钠通道阻滞剂的联芳基取代的噻唑、噁唑和咪唑
CN1788002A (zh) 作为钠通道阻滞剂的联芳基取代的三唑化合物
CN1794990A (zh) 代谢型谷氨酸受体－5的二芳基取代吡咯调节剂
CN1768055A (zh) 作为代谢型谷氨酸受体－5调制剂的四环咪唑衍生物
CN1612865A (zh) 作为环加氧酶(cox)抑制剂的三唑衍生物
CN1032648C (zh) 一种血小板活化因子拮抗剂的制备方法
CN1353705A (zh) 吡嗪酮凝血酶抑制剂
CN1064350C (zh) 芳基和杂芳基烷氧基萘衍生物
CN1029479C (zh) 新型苯并噁嗪衍生物的制备方法
CN1726206A (zh) 用作11－β－羟基类固醇脱氢酶－1抑制剂的三唑衍生物
EP1582519A2 (en) Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
HK1047929B (en) Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
CN1033051A (zh) 氮杂螺环化合物的制备和用途
CN1946715A (zh) 用于治疗糖尿病的杂芳基氨基吡唑衍生物
CN1835934A (zh) 作为环加氧酶抑制剂的噁唑衍生物

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: ASTRAZENECA AB

Free format text: FORMER OWNER: NPS PHARMACEUTICALS, INC.

Effective date: 20071123

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20071123

Address after: Swedish Sodertalje

Patentee after: Astrazeneca AB

Address before: American Utah

Patentee before: NPS Pharmaceuticals, Inc.

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070502

Termination date: 20110818